X0306 4 2017-07-05 0 0001645113 Novocure Ltd NVCR 0001654435 Danziger Asaf C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 1 1 0 0 Chief Executive Officer Ordinary Shares 2017-07-05 4 A 0 2545 6.673 A 899462 D Ordinary Shares 2017-07-05 4 S 0 155088 18.144 D 744374 D Ordinary Shares 2017-07-06 4 S 0 5050 18.088 D 739324 D The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2017 through June 30, 2017. This transaction is also exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 3, 2017. On July 5, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 155,088 shares in multiple trades at prices ranging from $18.00 to $18.35. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. On July 6, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 5,050 shares in multiple trades at prices ranging from $18.00 to $18.20. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. By: /s/ Todd Longsworth, Attorney in fact for Asaf Danziger 2017-07-07